BrightSpring Health Services, Inc. AI Stock Analysis
Want to see BTSG full AI Analyst Report?
BrightSpring Health Services, Inc. (BTSG) AI Stock Analysis
BrightSpring Health Services, Inc.
(NASDAQ:BTSG)
The score is driven primarily by improving financial performance (profitability recovery and strong free cash flow) and a very upbeat earnings outlook with raised/robust growth guidance. Technicals add support via a positive trend, while the main offset is valuation risk from a high P/E and lack of dividend yield support.
BrightSpring Health Services, Inc. (BTSG) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $14.20B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.44M
- Price to Earnings (P/E)
- 43.5
- Beta (1Y)
- 1.11
- Revenue Growth
- 22.86%
- EPS Growth
- 157.24%
- Country
- US
- Employees
- 23,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
BrightSpring Health Services, Inc. Business Overview & Revenue Model
Company Description
BrightSpring Health Services, Inc. operates across the United States, offering a range of healthcare solutions directly within patients' homes and local communities. The company's extensive platform focuses on providing crucial pharmacy and medical p...
How the Company Makes Money
BrightSpring primarily makes money by providing healthcare services and pharmacy services that are reimbursed by government programs and other payors. Its revenue model is largely fee-for-service (and, where applicable, contracted reimbursement) acro...
BrightSpring Health Services, Inc. Earnings Call Summary
The call was strongly positive, with substantial year-over-year growth in revenue, adjusted EBITDA, EPS, cash flow, specialty pharmacy, provider services, and home health. Management also raised or maintained robust 2026 and 2027 growth expectations, highlighted improving operational metrics, and described broad investment and acquisition opportunities. The principal negative item was the continued IRA-related pressure on Home and Community Pharmacy revenue, along with the limited near-term economic contribution expected from the ACO initiative.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, excluding the Community Living business and any acquisitions that have not yet closed, total revenue is expected to be in the range of $15.9 billion to $16.125 billion, including pharmacy solutions revenue of $14.0 to $14.2 billion and provider services revenue of $1.9 to $1.93 billion, reflecting 23.2 to 24.9% growth over full year 2025; total adjusted EBITDA is expected to be in the range of $850 million to $860 million, reflecting 37.6 to 39.3% growth over full year 2025, including an expected contribution of approximately $35 million from the Amedisys/LHC asset acquisition, while annual operating cash flow is anticipated to be at least $700 million excluding community living transaction related cash flow impacts, with EBITDA to operating cash conversion of approximately 80% and over $600 million of cash flow after CapEx and before debt pay down and share repurchases; for 2027, the company still expects organic adjusted EBITDA growth of at least 15% to 20%, with year over year adjusted EBITDA growth in each quarter similar to the overall growth for the year and year over year growth in the second half expected to be a little higher than the first half.
BrightSpring Health Services, Inc. Financial Statement Overview
Summary
Financials are improving with a clear profitability turnaround (TTM net income ~$338M) and strong cash generation (TTM operating cash flow ~$603M; free cash flow ~$492M, up ~22%). Balance sheet risk has moderated as equity rebuilt and leverage declined, but leverage remains meaningful (debt-to-equity ~1.17x) and margins are still thin with long-run gross margin compression.
Income Statement
72PositiveBalance Sheet
63PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.25B | 12.91B | 11.27B | 8.83B | 7.72B | 6.70B |
| Gross Profit | 1.91B | 1.52B | 1.59B | 1.43B | 1.35B | 1.25B |
| EBITDA | 709.15M | 459.53M | 398.13M | 349.52M | 391.80M | 433.34M |
| Net Income | 338.34M | 190.67M | -18.06M | -154.60M | -53.91M | 49.80M |
Balance Sheet | ||||||
| Total Assets | 6.27B | 6.41B | 5.93B | 5.53B | 5.44B | 5.51B |
| Cash, Cash Equivalents and Short-Term Investments | 717.84M | 88.37M | 61.25M | 13.07M | 13.63M | 46.73M |
| Total Debt | 2.38B | 2.71B | 2.90B | 3.67B | 3.68B | 3.77B |
| Total Liabilities | 4.08B | 4.53B | 4.27B | 4.92B | 4.66B | 4.71B |
| Stockholders Equity | 2.18B | 1.88B | 1.65B | 584.74M | 754.78M | 774.82M |
Cash Flow | ||||||
| Free Cash Flow | 492.41M | 394.69M | -57.14M | 137.26M | -74.77M | 210.90M |
| Operating Cash Flow | 602.74M | 490.17M | 23.77M | 210.78M | -4.65M | 270.17M |
| Investing Cash Flow | 462.12M | -305.08M | -140.24M | -134.43M | 45.36M | -1.19B |
| Financing Cash Flow | -488.32M | -157.87M | 164.65M | -76.91M | -73.81M | 705.22M |
BrightSpring Health Services, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTSG, the sentiment is Positive. The current price of 71.37 is above the 20-day moving average (MA) of 65.84, above the 50-day MA of 62.14, and above the 200-day MA of 56.35, indicating a bullish trend. The MACD of 2.86 indicates Negative momentum. The RSI at 65.15 is Neutral, neither overbought nor oversold. The STOCH value of 75.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BTSG.
BrightSpring Health Services, Inc. Risk Analysis
BrightSpring Health Services, Inc. disclosed 56 risk factors in its most recent earnings report. BrightSpring Health Services, Inc. reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskBrightSpring Health Services, Inc. Peers Comparison
Overall Rating
HNGE81Outperform
BTSG72Outperform
OMDA69Neutral
PRVA59Neutral
EVH58Neutral
TDOC56Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $9.86B | 58.17 | 50.47% | ― | 49.86% | ― | |
| 72Outperform | $14.20B | 43.52 | 16.75% | ― | 22.86% | 157.24% | |
| 69Neutral | $898.93M | 60.30 | 5.67% | ― | 43.34% | ― | |
| 59Neutral | $3.23B | 90.12 | 4.50% | ― | 19.19% | 84.88% | |
| 58Neutral | $546.30M | -1.07 | -129.54% | ― | 14.06% | -189.46% | |
| 56Neutral | $1.59B | -10.04 | -11.63% | ― | -2.38% | 32.73% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BTSG | BrightSpring Health Services, Inc. | 71.37 | 39.82 | 126.21% | |
| EVH | Evolent Health Inc. | 4.83 | 0.83 | 20.75% | |
| TDOC | Teladoc Inc. | 8.70 | 1.70 | 24.29% | |
| PRVA | Privia Health Group, Inc. | 25.26 | 2.13 | 9.21% | |
| HNGE | Hinge Health, Inc. Class A | 121.29 | 80.67 | 198.60% | |
| OMDA | Omada Health, Inc. | 14.49 | -4.52 | -23.78% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
